Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 15, 2017
Pharmacy Choice - News - Over-the-Counter Drugs - December 15, 2017

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 35     Next >>     Go To Page:

12/15/17 - Life Science Coalition Launches a Joint Policy Document on the Potential Impact of the United Kingdom's Exit From the European Union
Today, organisations representing the life science industry in the EU and the UK have called for medicines to be a priority in phase 2 of the Article 50 negotiations. Whilst being encouraged by the breakthrough in phase 1 of the negotiations so that the second phase can now begin, the sector states that focusing on the framework for transitional ar
12/15/17 - The Associations Representing the European and British Life Science Industry Have Today Launched a Joint Policy Document on the Potential Impact of the United Kingdom's Exit the European Union
Today, organisations representing the life science industry in the EU and the UK have called for medicines to be a priority in phase 2 of the Article 50 negotiations. Whilst being encouraged by the breakthrough in phase 1 of the negotiations so that the second phase can now begin, the sector states that focusing on the framework for transitional ar
12/14/17 - gel-e receives US FDA clearance to expand its bandage product line for Rx and OTC use
gel-e Inc., a privately held, clinical-stage medical device company, announces the 510 clearance of its adhesive bandage by the U.S. Food and Drug Administration for prescription and over-the-counter use. This new bandage clearance expands the Company's label to include the management of moderately to heavily exuding chronic wounds and acute woun
12/14/17 - New Ferring and Ache Laboratorios Farmaceuticos Facility Opens to Optimise Drug Delivery Using Nanotechnology
By a News Reporter-Staff News Editor at Women's Health Weekly Ferring Pharmaceuticals and Ache Laboratorios Farmaceuticos announced the inauguration of their joint nanotechnology centre in Sao Paulo, Brazil. Focused exclusively on nanotechnology research and development, the centre forms the first phase in a long term collaboration to optimise...
12/14/17 - Nuvo Pharmaceuticals Enters into Pennsaid 2% License Agreement with Gebro Pharma AG for Switzerland and Liechtenstein
-Nuvo Pharmaceuticals Inc., a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced it has entered into a license and distribution agreement with Gebro Pharma AG for the exclusive right to register, distribute, market and sell Pennsaid 2% in Switzerland and Liechtenst
12/14/17 - Nuvo Pharmaceuticals? Enters into Pennsaid 2% License Agreement with Gebro Pharma AG for Switzerland and Liechtenstein
-Nuvo Pharmaceuticals Inc., a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced it has entered into a license and distribution agreement with Gebro Pharma AG for the exclusive right to register, distribute, market and sell Pennsaid 2% in Switzerland and Liechtenst
12/14/17 - Two Day Seminar: The FDA Drug Approval Process (London, United Kingdom - March 22-23, 2018) - Research and Markets
It will also cover the organisation and structure of the Food and Drug Administration, recent amendments to the FDA's procedures designed to expedite the testing and approval of new medicines and other topics of current interest. Structure and functions of the FDA General regulatory requirements Regulation of preclinical and clinical research New d
12/14/17 - Two Innovus Pharma Products Officially Listed in OTC Section of the RED BOOK?
Innovus Pharmaceuticals, Inc., an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men s and women s health and vitality and respiratory diseases, today announced that t
12/13/17 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Data To Support Drug Product Communications as Used by the Food and Drug Administration
All comments should be identified with the OMB control number 0910-0695. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Testing of communication mess
12/13/17 - BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia Meeting
SAN RAFAEL, Calif.- BioMarin Pharmaceutical Inc. announced updates on valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia at ASH. Efficacy Data with Valoctocogene Roxaparvovec 4 e13 vg/kg Dose and 6 e13 vg/kg Dose as Presented at ASH. 'The confluence of new medicines and advanced treatment approaches for hemo
12/13/17 - FDA offers guidance on gluten-labeling for medications
This comes three years after the FDA set voluntary guidelines for labeling foods gluten free. We at Beyond Celiac formerly the National Foundation for Celiac Awareness have been working on addressing the issue of gluten in medications for a decade. said Alice Bast, Beyond Celiac CEO. Though the labeling is voluntary, it is definitely
12/13/17 - This Morning's Technical Outlook on Generic Drugs Stocks Versartis, Akorn, Rigel Pharma, and Medicines
Under evaluation for today are the following stocks: Versartis Inc., Akorn Inc., Rigel Pharmaceuticals Inc., and The Medicines Co.. Menlo Park, California headquartered Versartis Inc.' s shares plummeted 7.06%, closing Tuesday's trading session at $1.98. Additionally, shares of Versartis, which operates as an endocrine-focused biopharmaceutical com
12/12/17 - AbbVie Announces Phase 3 Study of VENCLEXTA?/ VENCLYXTO? (venetoclax) in Combination with Rituxan (rituximab) Meets its Primary Endpoint
AbbVie, a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Phase 3 study of VENCLEXTA?/ VENCLYXTO? in combination with Rituxan compared with bendamustine in combination with Rituxan in pat
12/12/17 - BioElectronics Announces ActiPatch: Over-The-Counter Alternative to Opioids
BioElectronics Corporation, the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today the launch of ActiPatch for Over-The-Counter, drug-free pain relief as an alternative to Opioids. ActiPatch is approved by the FDA for Over-The-Counter sales for the adjunctive treatment of pain due to: 1) Osteoarthritis
12/12/17 - BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
SAN RAFAEL- BioMarin Pharmaceutical Inc. announced today an update to its previously reported results of an open-label Phase 1/ 2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia A. The updated results will be presented during an oral presentation at the 59th American Society of Hematology Annual.
12/12/17 - BioPharmX Reports Third Quarter 2018 Financial Results
MENLO PARK, Calif.- BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, today announces its financial results for the third quarter ended October 31, 2017. 'We achieved important regulatory and financial milestones during the quarter,' said BioPharmX president Anja Krammer.' The Food and Drug Administration concurred
12/12/17 - New generic Viagra is here, cutting pharmacy bills for Michigan men in search of erections [Detroit Free Press]
Pfizer, the maker of Viagra, on Monday introduced the first official generic version of its blockbuster impotence pill. Some of the lowest consumer prices for generic Viagra are already offered by specialized pharmacies as well as new e-commerce startups, such as New York- based Roman Health, which has an online prescription service and mail-order
12/12/17 - Orexo Discloses More Information About the Improved Market Access Position for Zubsolv US in 2018
Orexo AB today announces specific information about the improved market access position for Zubsolv sublingual tablet in the US effective January 1, 2018, and previously announced in the Interim Report for the third quarter of 2017. Recently, the Formulary List of Covered Drugs for 2018 has been announced by all managed care programs, thus enabling
12/12/17 - Pharma and Healthcare Social Media Marketing Market Will Make a Huge Impact in Near Future: Pharma and Healthcare Social Media Marketing: Global Industry Analysis and Opportunity Assessment 2015 2025
Valley Cottage, NY 12/11/2017 Social media platforms refer to the interaction among the people that involves creation, sharing and exchange of information and ideas in virtual networks and communities. For instance, in second week of January 2014, the U.S. Food and Drug Administration released a guidance draft for industry that needs to fulfi
12/12/17 - Specialty pharmacy scrutiny hits again with state`s focus on Horizon meds [Tehran Times (Iran)]
In its 2015 and 2016 formularies, top pharmacy benefits manager Express Scripts excluded the pills, saying they were pricey substitutes for readily available, off-patent products. Horizon, however, says its single-pill formulations aren`t just more convenient for patients to take, but that the drugs` official FDA labels say the two brands have no r
12/12/17 - The Therapeutic Potential of Pharmacologically Active Cannabinoids
But InMed Pharmaceuticals, Inc. has initiated a scientific paradigm shift in discovering potential breakthrough cannabinoid-based therapies that advances far beyond basic cannabinoid production and the over-the-counter sales of oils and elixirs. The company s proprietary biosynthesis process sets it apart from the operations of companies like...
12/11/17 - BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting
BioMarin Pharmaceutical Inc. announced updates on valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia at ASH. Please see full release issued December 9, 2017 here for details. "The confluence of new medicines and advanced treatment approaches for hemophilia has created an unprecedented opportunity to impro
12/11/17 - Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Janssen Research& Development, LLC today announced it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for two new XARELTO vascular indications: reducing the risk of major cardiovascular events such as CV death, heart attack or stroke in patients with chronic coronary and/or peripheral artery disease,
12/11/17 - Multiple taxation, duties killing Nigerian manufacturers Nebe, Pharmatex MD [Sun, The (Nigeria)]
By Isaac Anumihe and Doris Obinna. Managing Director of Pharmatex Industries, Prince Christopher Obiora Nebe, was the sole representative of a multinational pharmaceutical company in Nigeria Hovid Industries before he ventured into drug manufacturing business, five years ago. Nebe listed some of the challenges of Nigeria s manufacturing se
12/11/17 - Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death for the Initial Treatment of Certain People with Advanced Kidney Cancer
Genentech, a member of the Roche Group, today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival and demonstrated that the combination of TECENTRIQ and Avastin provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or.
Articles(s): 1 - 25 of 35     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415